Marshall Wace
CAI

Marshall Wace’s Caris Life Sciences CAI Stock Holding History

Marshall Wace’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.97M Buy
+222,717
New +$3.99M ﹤0.01% 1487
2026
Q1 		– Sell
-1,002,734
Closed -$27.1M – 3787
2025
Q4 		$27.1M Buy
1,002,734
+919,759
+1,108% +$25.9M 0.02% 534
2025
Q3 		$2.51M Buy
82,975
+45,102
+119% +$1.44M ﹤0.01% 1500
2025
Q2 		$1.01M Buy
+37,873
New +$1.02M ﹤0.01% 1849

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace's CAI Position: Q2 2026 in Review

Marshall Wace opened a new position in Caris Life Sciences (CAI) in Q2 2026: 222,717 shares worth $3.97M. The stake represents ﹤0.01% of the portfolio and ranks #1487 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CAI as recently as Q4 2025.

Marshall Wace first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $27.1M in Q4 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Marshall Wace held 222,717 shares of Caris Life Sciences worth $3.97M as of Q2 2026.
  • Caris Life Sciences was a new Marshall Wace position in Q2 2026.
  • Caris Life Sciences made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1487 holding.
  • Marshall Wace first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Marshall Wace's Caris Life Sciences position peaked at $27.1M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.